VIA
BCYC

Virtus Investment Advisers’s Bicycle Therapeutics BCYC Stock Holding History

Virtus Investment Advisers’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Buy
80,789
+44,188
+121% +$203K 0.08% 351
2026
Q1 		$170K Buy
36,601
+892
+2% +$5.1K 0.05% 435
2025
Q4 		$253K Buy
35,709
+22,615
+173% +$167K 0.07% 321
2025
Q3 		$101K Buy
13,094
+2,273
+21% +$17.2K 0.03% 423
2025
Q2 		$75.2K Buy
10,821
+2,659
+33% +$21.2K 0.03% 433
2025
Q1 		$69.3K Buy
+8,162
New +$96.2K 0.02% 457

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Virtus Investment Advisers's BCYC Position: Q2 2026 in Review

Virtus Investment Advisers increased its Bicycle Therapeutics (BCYC) stake by 121% in Q2 2026, buying an estimated $203K and bringing the position to 80,789 shares worth $343K. The position accounts for 0.08% of the portfolio, ranked #351.

Virtus Investment Advisers first reported a position in BCYC in Q1 2025 and has held it in 6 quarters since. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Virtus Investment Advisers held 80,789 shares of Bicycle Therapeutics worth $343K as of Q2 2026.
  • Virtus Investment Advisers bought 44,188 Bicycle Therapeutics shares in Q2 2026, an estimated $203K.
  • Bicycle Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #351 holding.
  • Virtus Investment Advisers first reported a position in Bicycle Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.